{"schema":"hottub-news/prospects/v1","item":{"id":"n_uhsbqowspqlbg244jqxq","title":"Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer","title_en":null,"url":"https://www.2minutemedicine.com/durvalumab-plus-enfortumab-vedotin-was-approved-for-perioperative-treatment-of-muscle-invasive-bladder-cancer","outlet":"2minutemedicine.com","published":"2026-11-14T14:54:00Z","sponsored":false,"page":"https://hottub.news/articles/n_uhsbqowspqlbg244jqxq"},"prospects":[{"name":"2 Minute Medicine","kind":"person","role":"reporter","company":"2minutemedicine.com","website":"https://2minutemedicine.com/","source":"https://www.2minutemedicine.com/durvalumab-plus-enfortumab-vedotin-was-approved-for-perioperative-treatment-of-muscle-invasive-bladder-cancer","note":"Wrote: Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer","reason":"Reporter at 2minutemedicine.com; wrote “Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer” on 2026-11-14","group":"Reporters","add_url":"https://crm.joinhottub.com/relationships/add#name=2%20Minute%20Medicine&company=2minutemedicine.com&website=https%3A%2F%2F2minutemedicine.com%2F&source=https%3A%2F%2Fwww.2minutemedicine.com%2Fdurvalumab-plus-enfortumab-vedotin-was-approved-for-perioperative-treatment-of-muscle-invasive-bladder-cancer&note=Wrote%3A%20Durvalumab%20plus%20enfortumab%20vedotin%20was%20approved%20for%20perioperative%20treatment%20of%20muscle-invasive%20bladder%20cancer","propose":{"name":"2 Minute Medicine","kind":"person","reason":"Reporter at 2minutemedicine.com; wrote “Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer” on 2026-11-14","requestId":"news:n_uhsbqowspqlbg244jqxq:Reporter:643458a5:345f8d36","company":"2minutemedicine.com","website":"https://2minutemedicine.com/","sourceUrl":"https://www.2minutemedicine.com/durvalumab-plus-enfortumab-vedotin-was-approved-for-perioperative-treatment-of-muscle-invasive-bladder-cancer"}},{"name":"Reviewed Marc Succi","kind":"person","role":"reporter","company":"2minutemedicine.com","website":"https://2minutemedicine.com/","source":"https://www.2minutemedicine.com/durvalumab-plus-enfortumab-vedotin-was-approved-for-perioperative-treatment-of-muscle-invasive-bladder-cancer","note":"Wrote: Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer","reason":"Reporter at 2minutemedicine.com; wrote “Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer” on 2026-11-14","group":"Reporters","add_url":"https://crm.joinhottub.com/relationships/add#name=Reviewed%20Marc%20Succi&company=2minutemedicine.com&website=https%3A%2F%2F2minutemedicine.com%2F&source=https%3A%2F%2Fwww.2minutemedicine.com%2Fdurvalumab-plus-enfortumab-vedotin-was-approved-for-perioperative-treatment-of-muscle-invasive-bladder-cancer&note=Wrote%3A%20Durvalumab%20plus%20enfortumab%20vedotin%20was%20approved%20for%20perioperative%20treatment%20of%20muscle-invasive%20bladder%20cancer","propose":{"name":"Reviewed Marc Succi","kind":"person","reason":"Reporter at 2minutemedicine.com; wrote “Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer” on 2026-11-14","requestId":"news:n_uhsbqowspqlbg244jqxq:Reporter:5ec45824:345f8d36","company":"2minutemedicine.com","website":"https://2minutemedicine.com/","sourceUrl":"https://www.2minutemedicine.com/durvalumab-plus-enfortumab-vedotin-was-approved-for-perioperative-treatment-of-muscle-invasive-bladder-cancer"}},{"name":"MD (Harvard Medical School)","kind":"person","role":"reporter","company":"2minutemedicine.com","website":"https://2minutemedicine.com/","source":"https://www.2minutemedicine.com/durvalumab-plus-enfortumab-vedotin-was-approved-for-perioperative-treatment-of-muscle-invasive-bladder-cancer","note":"Wrote: Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer","reason":"Reporter at 2minutemedicine.com; wrote “Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer” on 2026-11-14","group":"Reporters","add_url":"https://crm.joinhottub.com/relationships/add#name=MD%20%28Harvard%20Medical%20School%29&company=2minutemedicine.com&website=https%3A%2F%2F2minutemedicine.com%2F&source=https%3A%2F%2Fwww.2minutemedicine.com%2Fdurvalumab-plus-enfortumab-vedotin-was-approved-for-perioperative-treatment-of-muscle-invasive-bladder-cancer&note=Wrote%3A%20Durvalumab%20plus%20enfortumab%20vedotin%20was%20approved%20for%20perioperative%20treatment%20of%20muscle-invasive%20bladder%20cancer","propose":{"name":"MD (Harvard Medical School)","kind":"person","reason":"Reporter at 2minutemedicine.com; wrote “Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer” on 2026-11-14","requestId":"news:n_uhsbqowspqlbg244jqxq:Reporter:d02dc550:345f8d36","company":"2minutemedicine.com","website":"https://2minutemedicine.com/","sourceUrl":"https://www.2minutemedicine.com/durvalumab-plus-enfortumab-vedotin-was-approved-for-perioperative-treatment-of-muscle-invasive-bladder-cancer"}},{"name":"2minutemedicine.com","kind":"organization","role":"outlet","website":"https://2minutemedicine.com/","source":"https://www.2minutemedicine.com/durvalumab-plus-enfortumab-vedotin-was-approved-for-perioperative-treatment-of-muscle-invasive-bladder-cancer","note":"Published: Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer (2026-11-14)","reason":"Published “Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer” on 2026-11-14","group":"Outlet","add_url":"https://crm.joinhottub.com/relationships/add#name=2minutemedicine.com&kind=organization&website=https%3A%2F%2F2minutemedicine.com%2F&source=https%3A%2F%2Fwww.2minutemedicine.com%2Fdurvalumab-plus-enfortumab-vedotin-was-approved-for-perioperative-treatment-of-muscle-invasive-bladder-cancer&note=Published%3A%20Durvalumab%20plus%20enfortumab%20vedotin%20was%20approved%20for%20perioperative%20treatment%20of%20muscle-invasive%20bladder%20cancer%20%282026-11-14%29","propose":{"name":"2minutemedicine.com","kind":"organization","reason":"Published “Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer” on 2026-11-14","requestId":"news:n_uhsbqowspqlbg244jqxq:Outlet:78f582fe:9b246813","website":"https://2minutemedicine.com/","sourceUrl":"https://www.2minutemedicine.com/durvalumab-plus-enfortumab-vedotin-was-approved-for-perioperative-treatment-of-muscle-invasive-bladder-cancer"}}],"someone_else":{"source":"https://www.2minutemedicine.com/durvalumab-plus-enfortumab-vedotin-was-approved-for-perioperative-treatment-of-muscle-invasive-bladder-cancer","note":"In the news: Durvalumab plus enfortumab vedotin was approved for perioperative treatment of muscle-invasive bladder cancer (2minutemedicine.com, 2026-11-14)"},"crm":{"name":"CRM by Hottub","add":"Open add_url in a browser: CRM by Hottub's add form, filled in. Nothing is saved until the person presses Add.","mcp":"https://crm.joinhottub.com/api/crm/mcp","tool":"propose_relationship","propose":"If you're connected to CRM by Hottub's MCP server with proposal access, call propose_relationship with `propose` as its arguments. An owner approves it before anything is added. Keep the arguments as given: retries reuse requestId."}}